- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117765
Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)
May 24, 2016 updated by: University of British Columbia
Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes
In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections.
Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span.
This is a pilot clinical trial to test the safety of a drug, ustekinumab, in 20 adult subjects with recent-onset T1D.
Ustekinumab is currently licensed for use in psoriasis where it has proven to be both highly effective and safe and so the investigators hope to see a similar effect in T1D.
This trial will also be used to determine the best dosage and frequency of the drug to be given to people with T1D to help design future studies on the drug's effectiveness.
The investigators hope that if the drug can block immune cells soon after the development of diabetes, any remaining insulin-producing cells may be protected, and regenerate, thus producing more insulin so that individuals may be insulin free, or require less insulin.
Study Overview
Detailed Description
The investigators will perform an open-label pilot safety study (Phase I/II clinical trial) with a total of 20 adult (18-35 years old) subjects with recent-onset T1D.
There will be four study cohorts, which will be recruited sequentially all to the treatment arm: five subjects will be given ustekinumab, 45mg subcutaneously (SC) at 0, 4, 16, 28 and 40weeks, five subjects will be given ustekinumab, 90mg SC at weeks 0, 4, 16, 28 and 40, five subjects will be given 45mg SC at weeks 0, 4 and 16 and five subjects will be given 90mg subcutaneously (SC) at weeks 0, 4 and 16.
Recruitment and screening for the pilot study will be completed within the first 6 months.
The follow up period is 1 year from the first dose.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- BC Diabetes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 33 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A diagnosis of type 1 diabetes mellitus in accordance with the canadian diabetes association criteria.
- An interval of ≤100 days between the diagnosis and the first dose of the study drug
- Ability to provide documented informed consent.
- Male or female, aged 18-35 years inclusive, at the time of the anticipated first dose of the study drug.
- Evidence of residual functioning β cells. This will be assessed by a C-peptide level over 0.2nmol/L in the MMTT test.
- Positive for at least one diabetes-related autoantibody.
- Willing to record all insulin taken and blood glucose levels that are required for monitoring during the study, including reporting any hypoglycaemic events.
Exclusion Criteria:
- No condition that, in the investigators' judgment, is likely to cause the subject to not be able to understand information in order to provide informed consent.
- History of malignancy.
- No significant and/or active disease in any body system that is likely to increase the risk to the subject or interfere with the subject's participation in the study.
- No significant systemic infection during the 6 weeks before the first dose of the study drug.
- No history of current or past active tuberculosis infection and no latent tuberculosis.
- Have used any other investigational drug within the 3 months prior to the first dose and/or intend on using any investigational drug for the duration of the study.
- Prior or current treatment that is known to cause a significant, ongoing change in the course of T1D or immunological status.
- Current or prior (within 30 days prior to first study drug dose) use of medications known to influence glucose tolerance.
- No significant abnormal laboratory values during the screening period, other than those due to T1D.
- Not pregnant, breastfeeding or planning to become pregnant during the 60 days after the last dose of the study drug.
- Have not received any live vaccines within 30 days prior to the first study drug dose and are not expected to need to receive a vaccine during the study.
- No prior allergic reaction, including anaphylaxis, to any component of the study drug product.
- No prior allergic reaction, including anaphylaxis, to any human, humanized, chimeric or rodent antibody treatment.
- Have not undergone any major surgery within the 30 day period prior to the first drug dose and not anticipating requiring surgery during the study period.
- Negative results for Hepatitis B surface antigen and for antibodies to Hepatitis B core antigen, or evidence of Hepatitis B surface antibody > 10 IU, and negative for Hepatitis C. Negative results for HIV and not considered by the investigator to be at high risk for HIV infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Four cohorts of 5 subjects will be recruited: Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks. Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks. Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks. Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Endpoints (composite outcome measure)
Time Frame: 12 months
|
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological Endpoints (composite outcome measure)
Time Frame: 12 months
|
|
12 months
|
Exploratory (composite outcome measure)
Time Frame: 12 months
|
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jan Dutz, MD FRCPC, Professor Department of Dermatology and Skin Science University of British Columbia
- Study Director: Ashish Marwaha, BMBCh PhD, University of British Columbia
- Study Director: Annika Sun, MSc, University of British Columbia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Anticipated)
February 1, 2017
Study Completion (Anticipated)
June 1, 2017
Study Registration Dates
First Submitted
April 7, 2014
First Submitted That Met QC Criteria
April 17, 2014
First Posted (Estimate)
April 21, 2014
Study Record Updates
Last Update Posted (Estimate)
May 25, 2016
Last Update Submitted That Met QC Criteria
May 24, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H14-00939
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Ustekinumab
-
Janssen Research & Development, LLCCompletedPsoriasisUnited States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
-
Janssen Research & Development, LLCCompletedPrimary Biliary CirrhosisUnited States, Canada
-
Samsung Bioepis Co., Ltd.CompletedPsoriasis | Moderate to Severe Plaque PsoriasisCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
-
Jewish General HospitalCompletedType 1 Diabetes MellitusCanada
-
Centocor, Inc.CompletedCrohn's DiseaseUnited States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
-
Janssen Research & Development, LLCCompletedPsoriasisFrance, Ukraine, United Kingdom, Germany, Portugal, Canada, Belgium, Russian Federation, Hungary, Sweden
-
Bioeq GmbHCompletedPlaque PsoriasisPoland, Estonia, Ukraine, Georgia
-
Centocor, Inc.Completed
-
Janssen Research & Development, LLCWithdrawnLupus Erythematosus, SystemicChina
-
Centocor, Inc.Completed